针对IL-5/5Ra向生物药物的现实世界有效性在严重的异敏性喘与并发性支气管切除症中
Sarah A Bendien1, Johannes A Kroes2, Lotte H G van Hal2
1Department of Pulmonology, Haga Teaching Hospital, The Hague, the Netherlands.
概括
抗IL-5/5Ra生物药物有效地降低了恶化和口服皮质类固醇 (OCS) 的使用在严重的乙酸性喘患者与支气管切除. 这些发现支持使用这些疗法,即使在并发性支气管炎症.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 支气管切除症是喘中常见的并发症,与疾病严重程度的增加有关.
- 抗干流素-5 (IL-5) /IL-5受体α (5Ra) 生物药物通过减少口服皮质类固醇 (OCS) 的使用和恶化,有利于严重的乙酸性喘患者.
- 支气管切除症对这些生物疗法的疗效的影响尚不清楚.
研究的目的:
- 评估抗IL-5/5Ra疗法的实际有效性.
- 评估对伴随性支气管切开症的严重乙酸性喘患者恶化频率和OCS剂量的影响.
主要方法:
- 一项现实研究分析了97名患有严重乙酸性喘和CT确诊的支气管病变的成年人的数据.
- 患者开始服用抗IL-5/5Ra生物药物 (梅波利祖马布,雷斯利祖马布,本拉利祖马布) 随访时间≥12个月.
- 分析包括了使用维护OCS和不使用维护OCS的子组.
主要成果:
- 抗IL-5/5Ra疗法在使用OCS和不使用OCS的患者中显著降低了恶化频率.
- 恶化从治疗前的74.5% (≥2年) 降低到治疗后的22.1%.
- 维持性OCS的患者比例从47%降至30%;依赖OCS的患者的中位数剂量从10.0降至2.5毫克/天.
结论:
- 抗IL-5/5Ra疗法有效地减少了严重的带有支气管切开症的疹性喘的恶化和OCS负担.
- 同病性支气管切除症不应成为这些患者抗IL-5/5Ra治疗的排除标准.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
375
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
375
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
358
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
358
01:20Asthma: Pathogenesis and Management
462
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
462
01:26COPD: Management Using Bronchodilators and Corticosteroids
255
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
255
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
316
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
316